Drug Profile
Efbemalenograstim alfa - Evive Biotech
Alternative Names: Benegrastim - Evive Biotech; Bineuta; F-627; rh G-CSF dimer; rh G-CSF Fc Fusion Protein; RyzneutaLatest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Generon (Shanghai) Corporation
- Developer Evive Biotech
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Neutropenia
- Discontinued Parkinson's disease
Most Recent Events
- 09 Feb 2024 Shandong University in collaboration with Chia Tai Tianqing Pharmaceutical plans a phase II trial for Neutropenia (Chemotherapy induced, Prevention) in China (SC, injection) in February 2024 (NCT06251947)
- 23 Nov 2023 Second Affiliated Hospital plans a phase II trial for Neutropenia (Prevention, Chemotherapy induced) in China (SC, Injection) in November 2023 (NCT06134765)
- 22 Nov 2023 Tianjin Medical University Cancer Institute and Hospital in collaboration with Chia Tai Tianqing Pharmaceutical group plans a phase II trial for Febrile neutropenia (In adults, In the elderly, Chemotherapy induced) in China (SC, Injection) (NCT06143735)